Aimmune Therapeutics, Inc. (NASDAQ:AIMT) marched up 5.56% compared to a 52-week low price of $21.22. The shares were last seen trading -4.52% lower, taking the closing price at $22.4 on 3/18/2019. At a recent session, the prices were hovering between $22.1007 and $23.29. This company shares are 132.54% off its target price of $52.09 and the current market capitalization stands at $1.39B. The recent change has given its price a -6.02% deficit over SMA 50 and -37.98% deficit over its 52-week high. The stock witnessed -5% declines, -0.93% declines and -23.29% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found AIMT’s volatility during a week at 3.43% and during a month it has been found around 4.74%.

Aimmune Therapeutics, Inc. (AIMT) Top Holders

Institutional investors currently hold around $1.08 billion or 83.4% in AIMT stock. Look at its top three institutional owners: Price T Rowe Associates Inc /Md/ owns $111.95 million in Aimmune Therapeutics, Inc., which represents roughly 8.05% of the company’s market cap and approximately 10.39% of the institutional ownership. Similar statistics are true for the second largest owner, Blackrock Inc., which owns 3,723,111 shares of the stock are valued at $87.34 million. The third largest holder is Vanguard Group Inc, which currently holds $86.22 million worth of this stock and that ownership represents nearly 6.2% of its market capitalization.

Aimmune Therapeutics, Inc. 13F Filings

At the end of December reporting period, 71 institutional holders increased their position in Aimmune Therapeutics, Inc. (NASDAQ:AIMT) by some 4,744,827 shares, 72 decreased positions by 2,981,479 and 18 held positions by 38,191,326. That puts total institutional holdings at 45,917,632 shares, according to SEC filings. The stock grabbed 21 new institutional investments totaling 2,067,981 shares while 33 institutional investors sold out their entire positions totaling 1,251,285 shares.

Aimmune Therapeutics, Inc. (AIMT) Analyst Guide

Several analysts have released their opinion on Aimmune Therapeutics, Inc. (NASDAQ:AIMT), with 3 analysts believing it is a strong buy. Whereas 2 of them predict the stock is a hold. Also, there are 6 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.91 average brokerage recommendation [T1].